Grants for Small businesses - Federal

The FY24 BCRP Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Patients contributions of tissue, serum, and other biologic specimens and their data are invaluable to saving lives. The BCRP has created this mechanism to help ensure that science values those contributions with research that maximizes their impact.The critical components of this award mechanism are:Impact: Research supported by the FY24 BCRP Clinical Research Extension Award will have the potential to extend or affect the impact of the previously funded clinical trial or study or will result in new impact and accelerate progress toward ending breast cancer.Research Scope: Although not all-inclusive, research proposed under the FY24 BCRP Clinical Research Extension Award may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis-testing or -generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms, including patient-derived models or tissue arrays. Innovation is not a criterion for this award mechanism. Projects proposing to conduct clinical trials will not be supported.Feasibility: Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The applicant must demonstrate availability of, and accessibility to, the necessary resources or populations to accomplish the proposed research.Data Evaluation and Sharing: Proposed research should be based on a study sample size that will ensure that the results support valid conclusions or will generate a meaningful hypothesis. It is the applicants responsibility to provide sufficient evidence that the sample size is appropriate to meet the studys objectives and outline the statistical methods and considerations they will employ in their data analysis. The applicant must outline a data-sharing plan for the scientific community to have access to the experimental platforms and molecular and other data generated from the proposed research.applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two Principal Investigators (PIs). One PI will be identified as the Initiating PI, who will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring a distinct contribution to the application. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. Applicants are discouraged from being named as a PI, Initiating PI, or Partnering PI on multiple Clinical Research Extension Award applications unless they are clearly addressing distinct research questions. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, and it is the applicants responsibility to outline the advocates role in the design and execution of the study. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they may not be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects that may or may not be considered a clinical trial. For this funding opportunity, research involving human subjects, human specimens, and data, including extended or expanded clinical follow-up of patients, is permitted; however, this award cannot be used to conduct clinical trials.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Clinical Research Extension Award should not exceed $5M for applications with a single PI or $6M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $18.6M to fund approximately two Clinical Research Extension Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides financial support for small businesses to develop innovative e-learning training products that enhance the safety and health training of workers dealing with hazardous materials and emergency response situations.

This funding opportunity provides financial support to organizations that empower young leaders in Southeast Asia to tackle climate change and environmental challenges through leadership training, collaboration, and capacity-building initiatives.

This funding opportunity is designed for small businesses to develop a Generative AI-based software system that creates realistic tactical data for military command and control operations, enhancing decision-making in challenging network environments.

This funding opportunity provides financial support to organizations that enhance leadership, management, and fiscal practices in Head Start and Early Head Start programs serving children and families.

The Energy CLASS (Champions Leading the Advancement of Sustainable Schools) Prize is a grant opportunity offered by the U.S. Department of Energy State and Community Energy Program Office (SCEP). The prize aims to support local education agencies in establishing and training energy managers to identify, plan, and implement efficiency and health upgrades in schools. With $80 million available, the grant will help schools across the country lower utility costs, improve indoor environmental quality, and reduce carbon emissions. The Energy CLASS Prize consists of two phases. In Phase 1, up to 25 selected LEAs will receive $100,000 in cash prizes to support participation in a 12-month training program. In Phase 2, participants will undergo 80-160 hours of online educational courses and receive one-on-one support and coaching related to building upgrades. At the end of Phase 2, participants can submit a progress report and a plan for future building upgrades for a chance to win a $50,000 bonus prize. To apply, LEAs need to submit a statement of need, letters of support, and demonstrate their commitment to making building energy upgrades. Interested applicants should review the official rules for complete application instructions. For updates or questions, applicants can subscribe on the HeroX platform or contact the Energy CLASS Prize team directly at [email protected].

This funding opportunity supports innovative research and community-driven projects that improve care and quality of life for individuals with Alzheimer's Disease and their caregivers.

This grant provides funding for small businesses to develop artificial intelligence solutions that improve the integration and data sharing between military systems, enhancing operational efficiency in tactical environments.

This funding opportunity supports research projects aimed at improving the management of multiple chronic diseases in low- and middle-income countries and American Indian/Alaska Native populations in the U.S. through innovative, community-centered healthcare strategies.

This funding opportunity supports the establishment of a Data Coordinating Center to manage and analyze data for multi-site clinical trials focused on heart, lung, and blood health research, aimed at a wide range of eligible organizations including universities and nonprofits.

This grant provides funding to U.S.-based organizations and institutions to develop advanced insulating glass technologies that significantly improve energy efficiency in buildings.

This funding opportunity supports research to implement and evaluate a fall prevention program for older adults in assisted living facilities, particularly targeting vulnerable populations at higher risk of falls.

This grant provides funding for researchers and organizations to conduct innovative studies in exobiology, focusing on the search for life beyond Earth and the conditions that support it.

This funding opportunity supports diverse institutions and researchers in conducting innovative research to promote health equity and improve health outcomes for all individuals, particularly by addressing social determinants of health and eliminating health disparities.

This funding opportunity supports institutions that have successfully completed an initial phase of a biomedical research program, enabling them to further develop research capabilities and enhance the careers of early-stage investigators.

This funding opportunity supports research to improve cancer care and outcomes for sexual and gender minority survivors by addressing their unique challenges and engaging community partners in the process.

This funding opportunity supports international collaborations to improve the detection and response to biological threats, particularly in developing countries, by enhancing biosurveillance and biosecurity capabilities.

This funding opportunity is designed for small businesses to develop AI technologies that improve the operation and safety of large ground combat vehicles, enhancing driver awareness and vehicle maneuverability in challenging environments.

This funding opportunity supports multi-site clinical trials for innovative treatments and interventions aimed at preventing or alleviating symptoms of Alzheimer's disease and related dementias, inviting applications from a diverse range of organizations and institutions.

With this solicitation, OVC seeks to award a 36-month cooperative agreement to one lead organization that will (1) fund (through a competitive process) subawards to communities severely affected by violence to establish trauma recovery centers , and (2) provide technical assistance to the subawardees to support operation of the centers. The trauma recovery centers funded under this demonstration project will address crime victimization and support access to victims compensation, crime victims rights enforcement, trauma recovery, and healing. Subawardees will be expected to design centers to provide services to crime victims who traditionally do not seek victims services, assistance, or counseling, or are historically underserved. This demonstration is intended to span 5 years (60 months total) via an initial 3-year budget allocation under this solicitation, with the potential for noncompetitive continuation funding as the project moves from year 3 to year 5 of its implementation.